Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling

Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling

Abstract Ciclopirox (CPX) is an antifungal drug that has recently been reported to act as a potential anticancer drug. However, the effects and underlying molecular mechanisms of CPX on glioblastoma multiforme (GBM) remain unknown. Bortezomib (BTZ) is the first proteasome inhibitor-based anticancer...

Full description

Bibliographic Details
Main Authors: Zhipeng Su, Shengnan Han, Qiumei Jin, Ningning Zhou, Junwan Lu, Fugen Shangguan, Shiyi Yu, Yongzhang Liu, Lu Wang, Jianglong Lu, Qun Li, Lin Cai, Chengde Wang, Xiaohe Tian, Lingyan Chen, Weiming Zheng, Bin Lu
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-03535-9

Internet

https://doi.org/10.1038/s41419-021-03535-9

Similar Items